Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : B Cell-based Therapy
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Be Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
MaxCyte Signs License with Be Biopharma for Engineered B Cell Medicines
Details : Be Bio gains non-exclusive research, clinical, and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT platform to support the development of its BCMs programs.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 02, 2024
Lead Product(s) : B Cell-based Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Be Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : WU-CART-007
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Wugen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
MaxCyte and Wugen Sign License to Expedite Manufacturing of Cell Therapies for Cancer
Details : Wugen gains non-exclusive clinical and commercial rights to MaxCyte’s Flow Electroporation® technology to support programs like WU-CART-007 for hematologic and solid tumors.
Brand Name : WU-CART-007
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 30, 2024
Lead Product(s) : WU-CART-007
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Wugen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Imugene
Deal Size : Undisclosed
Deal Type : Licensing Agreement
MaxCyte Signs License with Imugene To Advance Cancer Immunotherapy Programs
Details : Imugene has obtained commercial rights to use MaxCyte’s technology and ExPERT platform to support azer-cel, a potential allogeneic CD19 CAR T product candidate for blood cancer treatment.
Brand Name : PBCAR0191
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 23, 2024
Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Imugene
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : TCR-T Cell Therapy
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Lion TCR
Deal Size : Undisclosed
Deal Type : Licensing Agreement
MaxCyte and Lion TCR Partner To Expand TCR-T Cell Pipeline Globally
Details : Under the agreement, Lion TCR obtains worldwide non-exclusive rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for developing new TCR-T cell therapies for solid tumors.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 03, 2024
Lead Product(s) : TCR-T Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Lion TCR
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Genetic Therapy
Therapeutic Area : Genetic Disease
Study Phase : Discovery Platform
Sponsor : Prime Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform, to develop a new class of differentiated, one-time, potentially curative genetic therapi...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 01, 2023
Lead Product(s) : Genetic Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery Platform
Sponsor : Prime Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Viper 101
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Vittoria Biotherapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Vittoria will obtain rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform which will support its Senza5 technology to enhance efficacy of T-cell therapies including, Viper 101, a gene-edited, autologous, dual-population cell ther...
Brand Name : Viper 101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 10, 2023
Lead Product(s) : Viper 101
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Vittoria Biotherapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : B Cell-based Therapeutic
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Walking Fish Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Walking Fish will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 04, 2023
Lead Product(s) : B Cell-based Therapeutic
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Walking Fish Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : CAR-NK Cell Therapy
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Catamaran Bio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : CAT-248 is a CAR-NK cell therapy targeting CD70 positive tumors. CAT-248 has been engineered with four functional modifications: an optimized CAR that targets CD70, an IL-15 cytokine, a TME-switch, and the elimination of CD70 expression to enable scalabl...
Brand Name : CAT-248
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 03, 2023
Lead Product(s) : CAR-NK Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Catamaran Bio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Curamys
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Curamys
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Vertex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Vertex obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in the development of its CRISPR/Cas9-based gene-edited therapy (exa-cel, formerly k...
Brand Name : Exa-cel
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 28, 2022
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Vertex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?